• Exchange: NASDAQ GM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

ARQL:US

1.1450 USD 0.0150 1.33%

As of 10:33:30 ET on 12/29/2014.

Snapshot for ArQule Inc (ARQL)

Open: 1.1300 Day's Range: 1.1300 - 1.1700 Volume: 147,969
Previous Close: 1.1300 52wk Range: 1.0400 - 2.9200 1-Yr Rtn: -45.24%

Stock Chart for ARQL

No chart data available.
  • ARQL:US 1.1450
  • 1D
  • 1M
  • 1Y
1.1300
Interactive ARQL Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ARQL

Current P/E Ratio (ttm) 0.4522
Estimated P/E(12/2014) -
Relative P/E vs. SPX 0.0249
Earnings Per Share (USD) (ttm) 2.4991
Est. EPS (USD) (12/2014) -0.4700
Est. PEG Ratio -
Market Cap (M USD) 70.93
Shares Outstanding (M) 62.77
30 Day Average Volume 424,496
Price/Book (mrq) 1.6631
Price/Sale (ttm) 6.8477
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/05/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ARQL

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for ARQL

ArQule Inc. develops cancer therapeutics based on its proprietary Activated Checkpoint Therapy platform. The Company's platform is designed to produce small molecule compounds that selectively kill cancer cells while leaving normal cells unharmed. ArQule's products are intended to be effective against multiple types of cancer.

Paolo PucciChief Executive OfficerPeter S LawrencePresident/COO/Secy/Gen Cnsl
Brian SchwartzSenior VP/Chief Medical OfcrWilliam B BoniVP:Investor Relations
More Company Profile & Key Executives for ARQL

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil